The earnings call highlighted strong financial performance, record sales, and positive developments in the U.S. and international markets, along with strategic advancements in new channels and products. However, concerns over gross margin pressures and the conservative Q4 guidance tempered the overall positive sentiment.

Company Guidance

In the third quarter of 2024, Tandem Diabetes Care achieved notable financial milestones, delivering the highest quarterly sales in the company's history at $243 million, marking a 17% to 18% year-over-year growth, with $171 million from the U.S. and $72 million from outside the U.S. The company also reported a return to positive free cash flow of $22 million and an adjusted EBITDA profitability of 2% of sales. Gross margins were recorded at 51%, with expectations of easing pressures from the Mobi launch exiting 2024. Tandem's strategic focus includes expanding market share through its innovative products, such as Tandem Mobi and t:slim X2, and driving growth via new customer starts and MDI conversions. The company anticipates continued margin improvement and growth in 2025, leveraging new pharmacy channel strategies and expanding the use of its products for type 2 diabetes, with sales guidance set at $903 million to $910 million for 2024, reflecting strong operational execution and market demand.

Record-Breaking Quarterly Sales

Tandem Diabetes Care delivered the highest quarterly sales in the company's history, reaching $243 million in Q3 2024.

Positive Free Cash Flow

The company returned to positive free cash flow in the third quarter with a $22 million generation.

Strong U.S. Market Performance

U.S. sales reached $171 million, demonstrating over 23% year-over-year growth with nearly 21,000 pumps shipped.

International Growth

Outside the U.S., sales grew 31% year-over-year to $72 million, driven by strong demand and greater than anticipated distributor orders.

Pharmacy Channel Progress

Tandem signed its first agreement for the Tandem Mobi in the pharmacy channel, marking an important step in reducing patient out-of-pocket costs.

Clinical and Regulatory Advancements

Completion of pivotal trials for new products and successful regulatory clearance in the European Union for t:slim X2 with Lyumjev insulin.

---

Tandem Diabetes Care (TNDM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TNDM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 30, 2018	2018 (Q2)	- / -1.17	-4.4	73.41% (+3.23)	―	―
Nov 01, 2018	2018 (Q3)	- / -0.62	-3.552	82.55% (+2.93)	―	―
Feb 26, 2019	2018 (Q4)	- / 0.06	-1.23	104.96% (+1.29)	―	―
Apr 30, 2019	2019 (Q1)	- / -0.40	-1.82	78.02% (+1.42)	―	―
Aug 01, 2019	2019 (Q2)	- / -0.03	-1.17	97.44% (+1.14)	―	―
Nov 04, 2019	2019 (Q3)	- / -0.05	-0.62	91.94% (+0.57)	―	―
Feb 24, 2020	2019 (Q4)	- / 0.04	0.061	-34.43% (-0.02)	―	―
Apr 30, 2020	2020 (Q1)	- / -0.25	-0.4	37.50% (+0.15)	―	―
Jul 30, 2020	2020 (Q2)	- / -0.45	-0.03	-1400.00% (-0.42)	―	―
Nov 05, 2020	2020 (Q3)	- / -0.15	-0.05	-200.00% (-0.10)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

TNDM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2024	$34.24	$33.32	-2.69%
Aug 01, 2024	$35.21	$41.67	+18.35%
May 02, 2024	$36.56	$44.72	+22.32%
Feb 21, 2024	$22.55	$25.00	+10.86%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---